What To Know: Lilly Cites Circ. Opinions In 340B Data Clash
Pharmaceutical giant Eli Lilly & Co. cited two circuit opinions this week as it defended the legality of its threat to halt the flow of discounted drugs under the 340B pricing...To view the full article, register now.
Already a subscriber? Click here to view full article